Besides its ability to evade drug toxicity, melanoma can also develop adaptive tumor cell plasticity via tumor-microenvironment-dependent modifications [13,14,15], in response to treatment with BRAF/MEK inhibitors [10,11]. This evidence concerns the gene MAP2K7 and neoplasm.